Label Image (Lbl500904276)
Tadalafil
Product Images NDC 50090-4276
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50090-4276). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Tadalafil-fig1 (Tadalafil Fig1)
The text appears to be describing a graph (Figure 1), which shows the mean change in blood pressure in response to sublingual nitroglycerin at various time intervals after taking either Tadalafil or a placebo. The graph displays the difference between standing systolic blood pressure, standing diastolic blood pressure, supine systolic blood pressure, and supine diastolic blood pressure. The point estimate with a 90% confidence interval is also shown.*
Tadalafil-fig2 (Tadalafil Fig2)
This is a description of a study that involves the administration of Tadalafil and Doxazosin, with the dosage of Tadalafil being 20 mg and the dosage of Doxazosin being 8 mg. A placebo and Doxazosin at 8 mg were also administered. The study measured the mean change in systolic blood pressure over time after the administration of Doxazosin.*
Tadalafil-fig3 (Tadalafil Fig3)
This is a report from a study involving the use of 20mg of tadalafil and 8mg of doxazosin at different times throughout the day. The study measures the mean change from a time-matched baseline in systolic blood pressure. The text is not available for the figure produced.*
Tadalafil-fig4 (Tadalafil Fig4)
Plasma concentration of Tadalafil (a medication used to treat erectile dysfunction) is shown in this figure. The graph illustrates the concentration levels after administering a single dose of 20mg and once daily multiple doses of 5mg for five consecutive days. The x-axis displays the time in hours while the y-axis represents the concentration in mg/L. Error bars are shown for each data point to indicate variability.*
Tadalafil-fig5.jpg (Tadalafil Fig5)
This is a figure from Study J which compares the mean changes in IPSS total score in BPH patients by visit. The treatment duration in weeks is also shown on the X-axis. The medications being compared are Tatalafil 5 mg and placebo. No further information is available.*
Tadalafil-fig6.jpg (Tadalafil Fig6)
Tadalafil-fig7.jpg (Tadalafil Fig7)
The text describes a figure (Figure 7) showing the mean total IPSS changes by visit in patients with BPH taking Tadalafil and Finasteride for once-daily use. The figure shows the weeks of therapy along with the LS mean change from baseline, and indicates that the treatment difference is significant (p<0.001).*
Tadalafil-fig8.jpg (Tadalafil Fig8)
Tadalafil-str (Tadalafil Str)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
